[1] |
Broecker V, Mengel M. The significance of histological diagnosis in renal allograft biopsies in 2014[J]. Transpl Int, 2015, 28(2):136-143. doi: 10.1111/tri.2015.28.issue-2
|
[2] |
孙世澜.肾衰竭诊断治疗学[M].人民军医出版社, 2012.
|
[3] |
Yaich S. ABO-incompatible kidney transplantation[J]. Saudi J Kidney Dis Transpl, 2013, 24(3):463-472. doi: 10.4103/1319-2442.111009
|
[4] |
Muramatsu M, Gonzalez HD, Cacciola R, et al. ABO incompatible renal transplants: good or bad?[J]. World J Transplant, 2014, 4(1):18-29. doi: 10.5500/wjt.v4.i1.18
|
[5] |
Matsuo N, Yamamoto H, Kobayashi A, et al. A case of accelerated acute rejection after ABO-compatible living unrelated kidney transplantation[J]. Clin Transplant, 2009, 23(Suppl 20):23-26. doi: 10.1111/j.1399-0012.2009.01004.x/references
|
[6] |
Jalalzadeh M, Mousavinasab N, Peyrovi S, et al. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome[J]. Nephrourol Mon, 2015, 7(1):e24439. http://numonthly.com/24439.abstract
|
[7] |
Randhawa P. T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenges and clinical significance[J]. Curr Opin Organ Transplant, 2015, 20(3):325-332. doi: 10.1097/MOT.0000000000000189
|
[8] |
Zhang RB. Clinical management of kidney allograft dysfunction[J]. Open J Organ Transpl Surg, 2014, 4(2): 7-14. doi: 10.4236/ojots.2014.42002
|
[9] |
Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase Ⅲ clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation[J]. Transplantation, 1998, 66(1):29-37. doi: 10.1097/00007890-199807150-00005
|
[10] |
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 3):S1-S155. http://www.kdigo.org/clinical_practice_guidelines/pdf/KITxpGL_SupplementaryTables.pdf
|
[11] |
Salvadori M, Bertoni E. Acute antibody-mediated rejection in kidney transplantation: clinical and therapeutic aspects[J]. J Nephrol Ther, 2013, 4(1): 146. http://planthealth.org/article/acute-antibody-mediated-rejection-kidney-transplantation-clinical-and-therapeutic-aspects
|
[12] |
Melk A, Schmidt BM, Braun H, et al. Effects of donor age and cell senescence on kidney allograft survival[J]. Am J Transplant, 2009, 9(1):114-123. https://www.researchgate.net/profile/Philip_Halloran/publication/23768668_Effects_of_Donor_Age_and_Cell_Senescence_on_Kidney_Allograft_Survival/links/5408f2140cf2822fb738bb8f.pdf?inViewer=true&disableCoverPage=true&origin=publication_detail
|
[13] |
Allen U, Humar A, Limaye A, et al. Discipline of transplant infectious diseases (ID). foreword[J]. Am J Transplant, 2009, 9(Suppl 4):S1-S2. https://www.researchgate.net/publication/51441218_Discipline_of_Transplant_Infectious_Diseases_ID_Foreword
|
[14] |
Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial[J]. Am J Transplant, 2004, 4(3):438-443. doi: 10.1111/ajt.2004.4.issue-3
|
[15] |
Haririan A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation[J]. Curr Opin Nephrol Hypertens, 2015, 24(6):576-581. doi: 10.1097/MNH.0000000000000167
|
[16] |
Morath C, Zeier M. Transplantation: molecular diagnosis of kidney transplant rejection[J]. Nat Rev Nephrol, 2014, 10(8):429-430. doi: 10.1038/nrneph.2014.106
|
[17] |
Wilflingseder J, Reindl-Schwaighofer R, Sunzenauer J, et al. MicroRNAs in kidney transplantation[J]. Nephrol Dial Transplant, 2015, 30(6):910-917. doi: 10.1093/ndt/gfu280
|
[18] |
Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches[J]. Am J Transplant, 2014, 14(2):255-271. doi: 10.1111/ajt.12589
|
[19] |
Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes[J]. Transplant Rev, 2009, 23(1):34-46. doi: 10.1016/j.trre.2008.08.004
|
[20] |
Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review[J]. J Transplant, 2012:193724. https://www.hindawi.com/journals/jtrans/2012/193724/
|
[21] |
Kim M, Martin ST, Townsend KR, et al. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options[J]. Pharmacotherapy, 2014, 34(7):733-744. doi: 10.1002/phar.2014.34.issue-7
|
[22] |
Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24):2326-2333. doi: 10.1056/NEJMoa020009
|
[23] |
Heemann U, Lutz J. Pathophysiology and treatment options of chronic renal allograft damage[J]. Nephrol Dial Transplant, 2013, 28(10):2438-2446. doi: 10.1093/ndt/gft087
|
[24] |
Bhatti AB, Usman M. Chronic renal transplant rejection and possible anti-proliferative drug targets[J]. Cureus, 2015, 7(11):e376. http://assets.cureus.com/uploads/review_article/pdf/3505/1446833842-20151106-1538-182mb4z.pdf
|
[25] |
Tanabe K, Inui M. Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation[J]. Clin Transplant, 2013, 27(Suppl 26):2-8. doi: 10.1111/ctr.12260/references
|
[26] |
Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation[J]. Transplantation, 2013, 95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc
|